Herantis Pharma Oyj Logo

Herantis Pharma Oyj

Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.

HRTIS | ST

Overview

Corporate Details

ISIN(s):
FI4000087861
LEI:
743700W4CQVYAT3WKK38
Country:
Finland
Address:
Bertel Jungin Aukio 1, FI-02600 ESPOO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Herantis Pharma is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative conditions, with a primary emphasis on Parkinson's disease. The company's mission is to address significant unmet medical needs by creating treatments designed to stop or reverse disease progression. Its research and development efforts are centered on its proprietary technology platform, which includes lead drug candidates like HER-096, a therapy based on the Cerebral Dopamine Neurotrophic Factor (CDNF) protein.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Herantis Pharma Oyj filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Herantis Pharma Oyj

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Herantis Pharma Oyj via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan
4578
Outlook Therapeutics, Inc. Logo
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
United States of America
OTLK
Ovid Therapeutics Inc. Logo
Developing targeted small molecule therapies for rare neurological diseases and epilepsies.
United States of America
OVID
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland
OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom
OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom
OCTHF
Pacira BioSciences, Inc. Logo
Advancing non-opioid therapies for postsurgical, chronic, and musculoskeletal pain.
United States of America
PCRX
PAINREFORM LTD. Logo
Specialty pharma developing extended-release drugs for post-operative pain management.
United States of America
PRFX
PAION AG Logo
Developed drugs for hospital-based sedation, anesthesia, and critical care.
Germany
PA8
PALISADE BIO, INC. Logo
Developing oral precision therapies for inflammatory and fibrotic intestinal diseases like colitis.
United States of America
PALI

Talk to a Data Expert

Have a question? We'll get back to you promptly.